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Androgen deficiency in the aging male has become a topic 
of increasing interest and debate throughout the world. The 
demographics clearly demonstrate the increasing percentage 
of the population that is in the older age groups. The data also 
support the concept that testosterone falls progressively with age 
and that a significant percentage of men over the age of 60 years 
have serum testosterone levels that are below the lower limits 
of young adults (age 20-30 years) men. The principal questions 
raised by these observations are whether older hypogonadal 
men will benefit from testosterone treatment and what will be 
the risks associated with such intervention. The past decade has 
brought evidence of benefit of androgen treatment on multiple 
target organs of hypogonadal men and recent studies show 
short-term beneficial effects of testosterone in older men that are 
similar to those in younger men. Long-term data on the effects 
of testosterone treatment in the older population are limited and 
specific risk data on the prostate and cardiovascular systems are 
needed. Answers to key questions of functional benefits that may 
retard frailty of the elderly are not yet available. 
The recommendations described below were prepared 
for the International Society of Andrology (ISA) and the 
International Society for the Study of the Aging Male (ISSAM) 
following a panel discussion with active participation from the 
audience sponsored by the ISA on the topic at the 4th ISSAM 
Congress in Prague in February 2004. The ISA Member Societies 
were requested to comment on the draft recommedations. 
Representatives of the European Association of Urology (EAU) 
participated in the final draft of this document. This document 
is not intended to provide evidence for each recommendation as 
review of pertinent studies have recently been comprehensively 
summarized in the Clinical Research Directions on “Testosterone 
and Aging” by the Institute of Medicine (Washington 2004). The 
recommendations will be subject to revision as larger-scale 
and longer-term data become available. In order to reach a 
large audience these recommendations are published in the 
International Journal of Andrology,the Journal of Andrology, 
The Aging Male and in European Urology. 
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Recommendation  
Definition of late-onset hypogonadism (LOH): A clinical 
and biochemical syndrome associated with advancing age and 
characterized by typical symptoms and a deficiency in serum 
testosterone levels. It may result in significant detriment in 
the quality of life and adversely affect the function of multiple 
organ systems. 
Recommendation 2 
LOH is a syndrome characterized primarily by: 
1)  The easily recognized features of diminished sexual desire 
(libido) and erectile quality and frequency, particularly 
nocturnal erections, 
2)  Changes in mood with concomitant decreases in intellectual 
activity, cognitive functions, spatial orientation ability, 
fatigue, depressed mood and irritability, 
3)  Sleep disturbances, 
4)  Decrease in lean body mass with associated diminution in 
muscle volume and strength, 
5)  Increase in visceral fat, 
6)  Decrease in body hair and skin alterations,
7)  Decreased bone mineral density resulting in osteopenia, 
osteoporosis and increased risk of bone fractures. 
Recommendation  
In patients at risk or suspected of hypogonadism in general 
and LOH in particular a thorough physical and biochemical 
work-up is mandatory and especially, the following biochemical 
investigations should be done: 
1)  A serum sample for total testosterone determination and 
sex hormone binding globulin (SHBG) should be obtained 
between 07.00 and 11.00 hrs. The most widely accepted 
parameters to establish the presence of hypogonadism are 
the measurement of total testosterone and free testosterone 
calculated from measured total testosterone and SHBG 
or measured by a reliable free testosterone by dialysis 
method. 
2)  There are no generally accepted lower limits of normal and 
it is unclear whether geographically different thresholds 
depend on ethnic differences or on the physicians’ 
perception. There is however general agreement that total 
testosterone levels above 12 nmol/L (346 ng/dL) or free 
testosterone levels above 250 pmol/L (72 pg/mL) do not 
require substitution. Similarly, based on the data of younger 
men, there is consensus that serum total testosterone levels 
below 8 nmol/L (231 ng/dL) or free testosterone below 
 180 pmol/L (52 pg/mL) require substitution. Since 
symptoms of testosterone deficiency become manifest 
between 12 and 8 nmol/L, trials of treatment can be 
considered in those in whom alternative causes of these 
symptoms have been excluded (since there are variations 
in the reagents and normal ranges among laboratories, 
the cutoff values given for serum testosterone and free 
testosterone may have to be adjusted depending on the 
reference values given by each laboratory). 
3)  Salivary testosterone has been shown to be a reliable 
substitute for free testosterone measurements, but cannot 
be recommended at this time since the methodology has not 
been standardized and adult male ranges are not available 
in most hospital or reference laboratories. 
4)  If testosterone levels are below or at the lower limit of the 
accepted normal adult male values, it is recommended to 
perform a second determination together with assessment 
of serum luteinizing hormone (LH) and prolactin. 
Recommendation 4 
1)  It is recognized that significant alterations in other endocrine 
systems occur in association with ageing but the significance 
of these changes is not well understood. In general terms, 
determinations of thyroid hormones, cortisol, DHEA, 
DHEA-S, melatonin, GH and IGF-I are not indicated in 
the uncomplicated evaluation of late-onset hypogonadism. 
If endocrine disorders are suspected, assessment of these 
and other hormones may be warranted. 
2) Diabetes mellitus type 2 is a frequent disorder of ageing men. 
It is unclear at the present time what effect testosterone has 
on blood sugar and insulin sensitivity; thus, until positive 
effects of testosterone on blood sugar control are definitively 
demonstrated, diabetes should be evaluated and treated 
before or simultaneously with testosterone substitution. 
3)  In ageing men with the major complaint of erectile 
dysfunction, lipids and the cardiovascular status should be 
assessed. 
Recommendation 5 
A clear indication based on a clinical picture together with 
biochemical evidence of low serum testosterone should exist 
prior to the initiation of testosterone substitution. 
Recommendation 6 
1)  Testosterone administration is absolutely contraindicated 
in men suspected or having carcinoma of the prostate or 
breast. 
2)  Men with significant polycythemia, untreated sleep apnea, 
severe heart failure, severe symptoms of lower urinary 
tract obstruction evident by high scores in the IPSS 
(International Prostate Symptom Score) or clinical findings 
of bladder outflow obstruction (increased post-micturition 
residual volume, decreased peak urinary flow, pathological 
pressure flow studies) due to an enlarged, clinically benign 
prostate should not be treated with testosterone. Moderate 
obstruction represents a partial contraindication. After 
successful treatment of the obstruction, the contraindication 
is lifted. 
3)  In the absence of definite contraindications, age as such is not 
a contraindication to initiate testosterone substitution.
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Recommendation 7 
1)  Preparations of natural testosterone should be used for 
substitution therapy. Currently available intramuscular, 
subdermal, transdermal, oral and buccal preparations 
of testosterone are safe and effective. The treating 
physician should have sufficient knowledge and adequate 
understanding of the pharmacokinetics as well as of 
the advantages and drawbacks of each preparation. The 
selection of the preparation should be a joint decision of 
the patient and the physician. 
2)  Since the possible development of a contraindication 
during treatment (especially prostate carcinoma) requires 
rapid discontinuation of testosterone substitution, short-
acting (transdermal, oral, buccal) preparations should be 
preferred over long-acting (intramuscular, subdermal) 
depot-preparations in patients with LOH. 
3)  Inadequate data are available to determine the optimal 
serum testosterone level for efficacy and safety. For 
the present time mid to lower young adult male serum 
testosterone levels seem appropriate and should be the 
therapeutic goal. Supraphysiological levels must be avoided. 
Although it may appear desirable, no evidence exists for or 
against the need to maintain the physiological circadian 
rhythm of serum testosterone levels. 
Recommendation 8 
1) Alkylated androgen preparations such as 1a-methyl 
testosterone are obsolete because of their potential liver toxicity 
and should no longer be prescribed. 
2) There is not enough evidence to recommend a substitution 
with DHT in ageing men and there is no evidence to recommend 
other androgen preparations such as DHEA, DHEA-S, 
androstenediol or androstenedione for treatment. 
3) hCG stimulates testosterone production of Leydig cells, 
albeit at a lower rate in older than in younger men. Since 
insufficient information exists about the effects and side 
effects of hCG treatment in older men this treatment cannot be 
recommended in LOH. 
Recommendation  
Improvement in signs and symptoms of testosterone 
deficiency should be sought and failure to benefit clinical 
manifestations should result in discontinuation of treatment. 
Further investigation for other causes is then mandatory. 
Recommendation 0 
Digital rectal examination (DRE) and determination of 
serum prostate-specific antigen (PSA) are mandatory in men 
over the age of 45 years as baseline measurements of prostate 
health prior to therapy with testosterone, at quarterly intervals 
for the first 12 months and yearly thereafter. Transrectal 
ultrasound-guided biopsies of the prostate are indicated only 
if the DRE or the serum PSA levels are abnormal. 
Recommendation  
Testosterone normally results in improvements in mood and 
well-being. The development of negative behavioral patterns 
during treatment calls for dose modifications or discontinuation 
of therapy. 
Recommendation 2 
Polycythemia occasionally develops during testosterone 
treatment. Periodic hematological assessment is indicated, i.e. 
before treatment, three-monthly for one year and then annually. 
Dose adjustments may be necessary. 
Recommendation  
Bone density increases under testosterone substitution and 
fracture rates may be reduced. Therefore assessment of bone 
density at two-year intervals may be advisable (if available and 
affordable). 
Recommendation 4 
Some men with erectile dysfunction and low serum 
testosterone may not respond adequately under testosterone 
treatment alone. In these cases addition of phosphodiesterase 
5-inhibitors may be indicated. Similarly, men with erectile 
dysfunction not responding to phosphodiesterase 5-inhibitors 
may have low serum testosterone and require testosterone 
substitution. 
Recommendation 5 
Men successfully treated for prostate cancer and suffering 
from confirmed symptomatic hypogonadism are candidates for 
testosterone substitution after a prudent interval if there is no 
evidence of residual cancer. The risk and benefits must be clearly 
understood by the patient and the follow-up must be particularly 
careful. No reliable evidence exists in favor or against this 
recommendation. The clinicians must exercise good clinical 
judgment together with adequate knowledge of advantages and 
drawbacks of testosterone therapy in this situation.
